Evidence map›Paper›PMID 27504106›Full record

ArticleFrontiers in endocrinology2016

Prognostic Factors for Adrenocortical Carcinoma Outcomes.

Claudia Scollo, Marco Russo, Maria Antonietta Trovato, Daniela Sambataro, Dario Giuffrida, Mario Manusia, Giulia Sapuppo, Pasqualino Malandrino, Riccardo Vigneri, Gabriella Pellegriti

Registry-linked trialAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05344027 (The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma), which is not on this map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05344027 completednot on this mapstarted 2022, after this paper: background citation

The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma

TypeobservationalSponsorKing's College Hospital NHS TrustRan2022 to 2023Enrolled35ConditionsAdrenocortical CarcinomaArmsMitotane
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Asymmetric Adrenals: Sexual Dimorphism of Adrenal Tumors.The Journal of clinical endocrinology and metabolism · 2024
    Observational
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. The Sexually Dimorphic Adrenal Cortex: Implications for Adrenal Disease.International journal of molecular sciences · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Claudia ScolloEndocrinology, Department of Clinical and Experimental Medicine, University of Catania , Catania , Italy.
Marco RussoEndocrinology, Department of Clinical and Experimental Medicine, University of Messina , Messina , Italy.
Maria Antonietta TrovatoSurgical Oncology, Garibaldi-Nesima Hospital , Catania , Italy.
Daniela SambataroMedical Oncology, Garibaldi-Nesima Hospital , Catania , Italy.
Dario GiuffridaIstituto Oncologico del Mediterraneo, Viagrande , Catania , Italy.
Mario ManusiaPathology, Garibaldi-Nesima Hospital , Catania , Italy.
Giulia SapuppoEndocrinology, Department of Clinical and Experimental Medicine, University of Catania , Catania , Italy.
Pasqualino MalandrinoEndocrinology, Department of Clinical and Experimental Medicine, University of Catania , Catania , Italy.
Riccardo VigneriEndocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; Humanitas, Catania Oncology Center, Catania, Italy; Institute of Biostructures and Bioimaging, CNR, Catania, Italy.
Gabriella PellegritiEndocrinology, Department of Clinical and Experimental Medicine, University of Catania , Catania , Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAdrenocortical carcinoma (ACC) is an aggressive tumor characterized by a high recurrence rate and poor response to treatment. This study analyzes a consecutive series of ACC patients to evaluate the prognostic value of various clinical and pathological characteristics.

methodsWe retrospectively evaluated 32 ACC patients followed at our Medical Center from 1997 to 2015 and evaluated the prognostic value of age at diagnosis, gender, tumor functional status, stage, and type of treatment with respect to overall survival (OS) and disease-free survival (DFS), as determined by Kaplan-Meier curves.

resultsACC was associated with hormonal overproduction in 50% of cases, and patients with isolated hyperandrogenism had a better prognosis. Recurrence was observed in 12/26 (46.2%) patients with no evidence of disease after surgery. Tumor size [hazard ratio (HR) 1.32, 95% confidential intervals (CI) 1.12-1.64; p = 0.007], ki-67 (HR 1.06, 95% CI 1.02-1.11; p = 0.009) and advanced stage at diagnosis (III-IV) (HR 6.51, 95% CI 1.65-24.68; p = 0.006) were associated with recurrence in the 26 R0 patients in the univariate analysis. Advanced stage was an independent risk factor for recurrence in the multivariate analysis (HR 8.10, 95% CI 1.55-41.35; p = 0.01). Five-year survival was 40.0%. Positive resection margins (HR 10.61, 95% CI 3.02-38.31; p = < 0.001), ki-67 (HR 1.04, 95% CI 1.01-1.07; p = 0.01) and advanced stage (HR 11.31, 95% CI 1.45-87.76; p = 0.02) were associated with poor survival in all 32 patients, but only positive resection margins were an independent predictor of mortality in the multivariate analysis (HR 6.22, 95% CI 1.44-26.05; p = 0.01).

conclusionACC has a poor prognosis with a high recurrence rate. Tumor stage at diagnosis and the completeness of surgical excision are the most relevant prognostic factors.

Indexed as

adrenal canceradrenocortical carcinomaprognostic factorsrecurrencesurvival

Identifiers

PMID27504106
PMCPMC4958635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.